Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys
Open Access
- 1 March 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (5) , 2956-2963
- https://doi.org/10.1128/jvi.79.5.2956-2963.2005
Abstract
The development of a human immunodeficiency virus type 1 (HIV-1) vaccine that elicits potent cellular and humoral immune responses recognizing divergent strains of HIV-1 will be critical for combating the global AIDS epidemic. The present studies were initiated to examine the magnitude and breadth of envelope (Env)-specific T-lymphocyte and antibody responses generated by vaccines containing either a single or multiple genetically distant HIV-1 Env immunogens. Rhesus monkeys were immunized with DNA prime-recombinant adenovirus boost vaccines encoding a Gag-Pol-Nef polyprotein in combination with either a single Env or a mixture of clade-A, clade-B, and clade-C Envs. Monkeys receiving the multiclade Env immunization developed robust immune responses to all vaccine antigens and, importantly, a greater breadth of Env recognition than monkeys immunized with vaccines including a single Env immunogen. All groups of vaccinated monkeys demonstrated equivalent immune protection following challenge with the pathogenic simian-human immunodeficiency virus 89.6P. These data suggest that a multicomponent vaccine encoding Env proteins from multiple clades of HIV-1 can generate broad Env-specific T-lymphocyte and antibody responses without antigenic interference. This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1.Keywords
This publication has 29 references indexed in Scilit:
- Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidateVaccine, 2005
- Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus MonkeysJournal of Virology, 2004
- Cross-Clade T Lymphocyte-Mediated Immunity to HIV Type 1: Implications for Vaccine Design and Immunodetection AssaysAIDS Research and Human Retroviruses, 2002
- HIV-1 Diversity and Vaccine DevelopmentScience, 2002
- Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T CellsJournal of Virology, 2002
- Prospects for Vaccine Protection Against HIV-1 Infection and AIDSAnnual Review of Immunology, 2002
- Clinical Trials of HIV VaccinesAnnual Review of Medicine, 2002
- Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate EnvelopeJournal of Virology, 2001
- Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2000
- Potential Alterations in Immunogenicity by Combining or Simultaneously Administering Vaccine ComponentsaAnnals of the New York Academy of Sciences, 1995